NCT03961269 is a clinical trial in Breast Cancer Female, sponsored by Ali Sarfraz Siddiqui.

Who is sponsoring NCT03961269?

NCT03961269 is sponsored by Ali Sarfraz Siddiqui.

What condition does NCT03961269 study?

NCT03961269 studies Breast Cancer Female, Chronic Pain.

Is NCT03961269 still recruiting?

NCT03961269 is currently completed. Last updated 23 May 2019.

Last reviewed 2019-05-23 · How we verify

NCT03961269

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Frequency and Presentations of Chronic Pain Following Breast Cancer Surgery: An Observational Study in a Tertiary Care Hospital of Pakistan

Completed Last updated 23 May 2019

What this trial tests

trial in Breast Cancer Female in 120 participants. Completed in 15 July 2017.

Timeline

15 July 2016

Primary endpoint
15 July 2017

15 July 2017

Quick facts

Lead sponsor	Ali Sarfraz Siddiqui
Status	Completed
Study type	OBSERVATIONAL
Enrollment	120
Start date	15 July 2016
Primary completion	15 July 2017
Estimated completion	15 July 2017

Conditions studied

Breast Cancer Female — all drugs for Breast Cancer Female →
Chronic Pain — all drugs for Chronic Pain →

Sponsor

Ali Sarfraz Siddiqui

Who can join

Adults 30 to 75, female only, with Breast Cancer Female or Chronic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to evaluate the frequency and presentations of chronic persistent pain in patients after breast cancer surgery at our tertiary care hospital. Results of this study will help us to understand the magnitude of problem in our population and making institutional guidelines for appropriate management of such patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Breast Cancer Female

Currently open trials in the same condition.

NCT07505797 — ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) · recruiting
NCT07198724 — ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrin · Phase 1, PHASE2 · recruiting
NCT07331506 — Validation of the Oncoliq Test for the Early Detection of Breast Cancer. · recruiting
NCT07214883 — UCF MammoChat: Image Repository · recruiting
NCT07120100 — Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Surviv · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03961269 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ali Sarfraz Siddiqui
Last refreshed: 23 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03961269.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing